Viewing Study NCT06567860



Ignite Creation Date: 2024-10-26 @ 3:38 PM
Last Modification Date: 2024-10-26 @ 3:38 PM
Study NCT ID: NCT06567860
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: None
First Post: 2024-08-20

Brief Title: Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations
Sponsor: None
Organization: None

Study Overview

Official Title: Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Every 1-2 years the seasonal influenza vaccine composition changes to include updated viruses yet the precise effects of updating the vaccine remain understudied Since the vaccine formulation for each season with a season defined as starting in July and ending the following June expires on June 30 vaccine formulations cannot be compared head-to-head Thus the 2023 and 2024 vaccines have only been compared by analyzing people given the former vaccine in the fall of 2023 and people given the latter vaccine in the fall of 2024 and baseline repertoires may have greatly changed over the course of that year To that end the investigators will vaccinate a cohort with the 2023 influenza vaccine between May-June 2024 in order to compare responses between individuals receiving the 2023 vaccine last fall the 2023 vaccine late in the season this cohort and the 2024 vaccine next fall The investigators will further assess whether the late-season 2023 vaccine primed this cohort to respond better to the standard 2024 vaccine with standard timing vaccine administered around September-October
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None